Cormorant Asset Management's book
39 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Freenome | Decision/Risk Analysis | $2.2B | — | — | |
| Neurona Therapeutics | Drug Discovery | $1.1B | — | — | |
| Parabilis Medicines | Drug Discovery | $920.0M | — | — | |
| Tessera Therapeutics | — | $650.0M | — | — | |
| Latigo Bio | — | $530.0M | — | — | |
| Electra Therapeutics | Drug Discovery | $479.0M | — | — | |
| Supira Medical | — | $445.0M | — | — | |
| Umoja Biopharma | — | $420.0M | — | — | |
| AgomAb | Drug Discovery | $415.6M | — | — | |
| BlossomHill Therapeutics | — | $413.1M | — | — | |
| + 29 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 39 recorded positions
- ·Watchlist + alerts for Cormorant Asset Management's activity
Create free account
No card required